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Endoscopy in IBD has tremendous importance to diagnose inﬂammatory activity, to evaluate therapeutic success and for the
surveillance of colitis associated cancer. Thus it becomes obvious that there is a need for new and more advanced endoscopic
imaging techniques for better characterization of mucosal inﬂammation and early neoplasia detection in IBD. This paper
describes the concept of advanced endoscopic imaging for the diagnosis and characterization of Crohn’s disease, including
magniﬁcation endoscopy, chromoendoscopy, balloon-assisted enteroscopy, capsule endoscopy, confocal laser endomicroscopy,
and endocytoscopy.
1.Introduction
Inﬂammatory bowel disease (IBD) comprises two major
entities, ulcerative colitis (UC) and Crohn’s disease (CD).
It is now well accepted that both patient groups are at an
increased risk of developing colitis-associated cancer (CAC)
[1]. Chronic inﬂammation of the gastrointestinal mucosa
representsanimportantfactorforthedevelopmentofcolitis-
associated cancer (CAC). Thus, chronic administration of
anti-inﬂammatory drugs has been proposed to lower the risk
for CAC. However, most studies could not demonstrate that
commonly used anti-inﬂammatory drugs for treatment of
I B Dh a v ec h e m o p r e v e n t i v ee ﬀects against cancer [2]. There-
fore, new attempts have been made to better characterize
the development of mucosal inﬂammation in IBD in order
to establish more eﬀective preventive and targeted therapies.
Indeed,veryrecentlyitwasshownbyG¨ untherandcoworkers
that the cystein protease caspase 8 is critically involved in
regulating intestinal homeostasis and in protecting intestinal
epithelial cells from TNF-α-induced necroptotic cell death
thereby suggesting new therapeutic approaches in IBD [3].
While all patients with IBD suﬀer from an increased risk
for developing CAC, it was shown that the duration and
anatomical extent of disease are well-established risk factors
for cancer development. Correspondingly, patients with a
course of disease longer than 10 years or pancolitis are at
anincreasedrisk[4].Therefore,most guidelines recommend
surveillance colonoscopy as the gold standard for diagnosis
of intraepithelial neoplasia and cancer in IBD [4].
Nevertheless, to date, no randomized controlled study
could show a reduced risk of CAC development by surveil-
lance colonoscopy in IBD [5]. In this context, one retrospec-
tive case-control study assessed the severity of inﬂammation
as a risk factor for CAC in UC and found that inﬂammation
measured by endoscopy, which was signiﬁcant at univariate
analysis, was not a signiﬁcant determinant of cancer risk in
am u l t i v a r i a t em o d e l[ 6]. Only the degree of inﬂammation
over time as assessed by histopathology was considered to
be an independent risk factor for CAC development [6].
This ﬁnding was conﬁrmed by Mathy and coworkers who
demonstrated that histologic, rather than endoscopic assess-
ment of inﬂammation, serve asa better determinant forCAC
risk [7]. Although CAC may occur in elevated protruded
lesions, it may also develop in normal-appearing (i.e., “ﬂat”)
mucosa. Data from the literature indicate that in 50%–
80% of cases with colitis-associated neoplasms the lesions2 Gastroenterology Research and Practice
Figure 1: High-deﬁnition white-light endoscopy of severe Crohn’s
disease with multiple longitudinal ulcers and spontaneous bleeding
of the inﬂamed mucosa.
are not visible upon endoscopy [8]. This aspect limits the
usefulness of colonoscopic visualization and mandates the
need for multiple random biopsies, which is a time-con-
suming, costly, and ineﬀective endeavour.
Thus it becomes obvious that there is a need for new
and more advanced endoscopic imaging techniques for sur-
veillance in IBD. In recent years, new emerging endo-
scopic imaging techniques were introduced, allowing a de-
tailed analysis of more mucosal and submucosal details. This
paper describes the concept of advanced endoscopic imaging
for the diagnosis and characterization of Crohn’s disease.
2.AdvancedEndoscopic ImagingMethods
2.1. Magniﬁcation Endoscopy and Dye-Based Chromoen-
doscopy. Magniﬁcation endoscopy utilizes a movable lens to
vary the degree of magniﬁcation up to 150-fold, thereby
allowing to characterize the mucosal surface (e.g., pit pattern
classiﬁcation of colon polyps as suggested by Kudo et al. in
1996) [9] (Figures 1 and 2).
Chromoendoscopy is divided into dye-based chromoen-
doscopy (DBC) and dye-less chromoendoscopy (DLC).
DLC is further comprised of optical chromoendoscopy and
virtual chromoendoscopy. The basic principle of chromoen-
doscopy is to enhance the mucosal detail and/or submu-
cosal vascular network with the use of various dyes or
endoscopic/optical and computer-based color programs.
The contrast enhancement of the mucosal surface often
results in an improved detection of subtle lesions. DBC uses
diﬀerent dye agents which are divided into absorptive agents
(Lugol, methylene blue, toluidine blue, and cresyl violet),
contrast agents (indigo carmine, acetic acid) and reactive
staining agents (congo red, phenol red). Dye agents are
mostly applied via standard spraying or plain biliary ERCP
catheters [10]. Various studies have shown the potential of
chromoendoscopy to enhancedetection of preneoplastic and
neoplastic lesions in IBD. One randomized, controlled trial
evaluated whether chromoendoscopy using 0.1% methylene
Figure 2: High-magniﬁcation endoscopy using i-scan with surface
enhancement and tone enhancement clearly visualizes individual
intestinalvilliwithnormalshapeandsizeinapatientwithquiescent
Crohn’s disease.
blue might facilitate early detection of intraepithelial neo-
plasia and CAC in UC. Chromoendoscopy permitted more
accurate diagnosis of extent and severity of inﬂammatory
activity in UC compared with conventional colonoscopy and
improved signiﬁcantly the early detection of intraepithelial
neoplasia and CAC in patients with UC [11]. Another
back-to-back colonoscopy study evaluated pancolonic chro-
moendoscopy with 0.1% indigo carmine for detection of
dysplasia in UC. Nontargeted biopsies detected no dysplasia
in 2904 biopsies, while the targeted biopsy protocol with
pancolonic chromoendoscopy required fewer biopsies (157)
and detected nine dysplastic lesions [12]. These results were
conﬁrmed in a large prospective trial including 102 patients
with chronic colitis using chromoendoscopy with methylene
blue. Targeted biopsies with dye spray revealed signiﬁcantly
more dysplasia than random biopsies and more than the
targeted nondye spray protocol [13]. A meta-analysis of
six randomized controlled trials evaluated the diagnostic
accuracy of chromoendoscopy for dysplasia detection in
UC. The meta-analysis demonstrated a pooled sensitivity of
83.3%,speciﬁcityof91.3%,anddiagnosticoddsratioof17.5.
It was concluded that chromoendoscopy has a medium-to-
high sensitivity and a high diagnostic accuracy for detection
of dysplastic lesions in UC [14].
Typical endoscopic aspects of conventional endoscopy
and chromoendoscopy were recently summarized by the
group from the Hyogo College of Medicine in Japan [15].
Hurlstone and coworkers analyzed high-magniﬁcation
chromoscopiccolonoscopyinUCasatoolforreliableassess-
ment of disease extent [16]. 325 patients were prospectively
included, and magniﬁcation endoscopy was signiﬁcantly
better than conventional colonoscopy for predicting dis-
ease extent in vivo. The same group prospectively analyzed
indigo carmine-assisted high-magniﬁcation chromoscopic
colonoscopy for the detection and characterisation of intra-
epithelial neoplasia in UC. Signiﬁcantly more intraepithe-
lial neoplastic lesions were detected in the magniﬁcation
chromoendoscopygroupcomparedwithcontrols.Moreover,
chromoendoscopy increased the number of ﬂat lesions withGastroenterology Research and Practice 3
Figure 3: Large ulcer examined with narrow band imaging. NBI
visualizes irregular surface architecture and disturbed vascular
structures. Histopathology conﬁrmed diagnosis of cancer.
intraepithelial neoplasia detected compared with controls
[17].Anothergroupstudiedthepitpatternsinrectalmucosa
by magnifying colonoscopy as a marker of relapse in patients
with quiescent UC [18]. Multivariate proportional hazard
model analysis showed that pit pattern analysis using magni-
ﬁcation endoscopy could signiﬁcantly predict relapse of dis-
easeinpatientswithquiescentulcerativecolitis.Theseresults
were also conﬁrmed by Watanabe and coworkers [19].
(i) Pancolonic chromoendoscopy and targeted biopsies
of suspicious lesions represent a more eﬀective
surveillancemethodinIBDthantakingonlymultiple
nontargeted biopsies.
(ii) Magniﬁcation chromoendoscopy improves the de-
tection of preneoplastic and neoplastic mucosal
changes.
(iii) Magniﬁcation endoscopy has the potential to predict
relapse in patients with quiescent disease.
2.2. Dye-Less Chromoendoscopy. DLC is divided into optical
chromoendoscopy including narrow band imaging (NBI;
Olympus, Tokyo, Japan Figure 3) and virtual chromoen-
doscopy including i-scan (Pentax, Tokyo, Japan Figure 4)
and Fujinon intelligent color enhancement (FICE; Fujinon,
Tokyo,Japan).WhileNBIisbasedonopticalﬁlterswithinthe
light source of the endoscope which narrow the bandwidth
of spectral transmittance, thereby enhancing blood vessels,
i-scan and FICE use digital postprocessing for computed
spectral estimation for better tissue contrast [20].
Various studies have addressed the potential of NBI
for diagnosis and characterization of preneoplastic and
neoplastic changes in IBD. One recent published article
reviews endoscopic ﬁndings under narrow band imaging.
It was shown that NBI ﬁndings strongly correlated with
histologic ﬁndings including crypt distortion, goblet cell
depletion,andbasalplasmacytosis,therefore,harbouringthe
potential to better assess histologic severity in only mild
and inactive disease [21]. Very recently, van den Broek and
coworkers performed a randomized crossover trial in which
patients with UC underwent both NBI and high-deﬁnition
(HD) white-light colonoscopy in a randomized order. It
was shown that NBI does not improve the detection of
neoplasia in patients with UC compared to HD endoscopy.
In addition, NBI proved unsatisfactory for diﬀerentiating
neoplastic from nonneoplastic mucosa [22]. The same group
assessed the value of endoscopic trimodal imaging for
surveillance in UC. Fifty patients underwent surveillance
colonoscopy and each colonic segment was inspected twice,
once with autoﬂuorescence imaging (AFI) and once with
white-light endoscopy, in random order. All detected lesions
were inspected by NBI for Kudo pit pattern analysis and
additional random biopsies were taken. AFI improved the
detection of neoplasia and decreased the yield of random
biopsies. Pit pattern analysis by NBI has a moderate accuracy
for the prediction of histology, whereas AFI colour appears
valuable in excluding the presence of neoplasia [23]. Kudo
et al. analyzed the mucosal vascular pattern (MVP) in UC
using both conventional and NBI colonoscopy. In this study,
N B Ic o l o n o s c o p yw a sm o r ep r e c i s et od e t e r m i n et h eg r a d e
of inﬂammation in patients with quiescent UC compared
to histology as the gold standard [24]. In another study,
the same group performed a pilot study of magniﬁcation
colonoscopy with NBI for diagnosis of dysplasia in UC. The
surface pattern was determined to be either honeycomblike,
villous, or tortuouslike. By taking the surface pattern into
account, the rate of positive dysplasia was higher in the
tortuous pattern than in the honeycomblike or villous
pattern group. Therefore, the tortuous pattern determined
by NBI colonoscopy may be a clue for the identiﬁcation of
dysplasia during surveillance for UC [21]. Very recently it
was also shown that NBI appears to be a less timeconsuming
and equally eﬀective alternative to chromoendoscopy for
the detection of intraepithelial neoplasia. NBI resulted in
a signiﬁcantly inferior false-positive biopsy rate and a
similar true-positive rate. However, given the NBI lesion
and patient miss rates, NBI could not be recommended as
the standard surveillance technique in IBD [25]. Another
pilot study addressed the question if NBI could successfully
assess mucosal angiogenesis in IBD. In areas that were
endoscopically normal but positive on NBI, there was a
signiﬁcant increase in mucosal angiogenesis. Therefore, NBI
may allow in vivo imaging of intestinal neoangiogenesis in
IBD patients [26].
Only limited data are currently available on virtual
chromoendoscopy techniques in IBD. Up to now, only one
study evaluated FICE in the IBD setting, showing that the
system could not improve the detection or delineation of
u l c e r sa n de r o s i o n si nC D[ 27]. Another study compared
chromoendoscopy with methylene blue (0.1%) and HD
colonoscopyusingi-scan.HDcolonoscopywithandwithout
i-scan was feasible to unmask a plethora of small lesions
but chromoendoscopy could even increase the number.
Moreover, i-scan was able to predict neoplasia as precisely
as chromoendoscopy [28]. A randomized controlled study
evaluated HD colonoscopy in conjunction with i-scan or
standard video colonoscopy for the detection of colorectal
lesions. HD endoscopy with i-scan detected signiﬁcantly4 Gastroenterology Research and Practice
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Figure 4: (a) highlights high-deﬁnition white-light endoscopic picture of anastomotic stricture in a patient suﬀering from Crohn’s disease.
(b) shows virtual chromoendoscopy with i-scan to better characterize the stricture. i-scan revealed enhanced vasculature and ﬁbrinous
lesions consisting with an active inﬂammation.
more patients with colorectal neoplasia (38%) compared
with standard resolution endoscopy (13%). Signiﬁcantly
more neoplastic lesions and more ﬂat adenomas could
also be detected using HD endoscopy with i-scan [29].
Recently, our group successfully studied the impact of i-
scanforpredictionofmucosalinﬂammationinIBD.Patients
underwent total colonoscopy and were examined using both
HD (Group A) and HD plus i-scan colonoscopy (Group B).
Agreementbetweenendoscopicpredictionofdiseaseseverity
and histologic ﬁndings was 65% in group A and 88% in
group B. When comparing the endoscopic prediction of
extent of inﬂammatory activity with the histologic results
from the corresponding specimens, we found agreement
in 42% in group A and 85% in group B. Compared
with histological results of inﬂammation, i-scan signiﬁcantly
enabled more precise diagnosis of mucosal inﬂammation
compared to conventional colonoscopy [30].
(i) Dye-less chromoendoscopy oﬀers the potential to
replace conventional dye-based chromoendoscopy
forlesiondetectionandassessmentofdiseaseseverity
in IBD.
(ii) Virtual chromoendoscopy with i-scan is superior
to standard video colonoscopy for the detection of
colorectal neoplasia.
(iii) i-scan signiﬁcantly improves the diagnosis of severity
and extent of mucosal inﬂammation in patients with
IBD.
2.3. Balloon-Assisted Enteroscopy. Although standard small-
bowel endoscopy plays a pivotal role in the management
of patients with IBD, its location in the diagnosis and
treatmentalgorithmisstillnot clearlydeﬁned[31].Theterm
“balloon-assisted enteroscopy” (BAE) was ﬁrst proposed by
M¨ onkem¨ uller and coworkers and summarizes three diﬀerent
endoscopic methods for small-bowel imaging: (1) double-
balloon enteroscopy (DBE; Fujinon, Tokyo, Japan); (2)
Figure 5: Confocal laser endomicroscopy reveals normal appearing
microvessels within the lamina propria and colonic crypts regular
in size and shape in patient with quiescent Crohn’s disease.
single-balloon endoscopy (SBE; Olympus, Tokyo, Japan);
(3) NaviAid (Pentax, Tokyo, Japan). All systems allow
deep intubation of the small bowel for diagnostic and
therapeutic interventions (e.g., for hemostasis, dilation, or
biopsy acquisition). Combination of oral and anal insertion
routes are used is to achieve complete examination of the
small bowel [32].
Uptonowfewstudieshavereporteda30–48%diagnostic
yield of DBE when evaluating patients with suspected
Crohn’s disease [32–36]. Complications are rare and occur
in <1% of cases while balloon dilation of strictures has a
reportedperforationriskofupto3%[34].Nevertheless,BAE
should not be considered as the ﬁrst-line procedure in the
evaluation of suspected small-bowel CD, as the procedure
is somehow invasive, time- and cost- expensive, and mostlyGastroenterology Research and Practice 5
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Figure 6: Endocytoscopy with 1390-fold magniﬁcation in quiescent (a) and active (b) Crohn’s disease. Endocytoscopy enables clear
visualization of diﬀerent cellular structures within the intestinal mucosa, including the size, arrangement, and density of cells.
limitedtospecializedcenters.Therefore,inpatientswithsus-
pected small-bowel CD without strictures or stenosis capsule
endoscopy should ﬁrstly be considered [31]. However, BAE
allows for the retrieval of tissue for analysis and permits
therapeutic interventions such as stricture dilation.
2.4. Capsule Endoscopy. Capsule endoscopy (CE) was intro-
duced in 2002. Currently, various capsule systems from dif-
ferent companies are available for examination of the esoph-
agus, small bowel, and colon [36]. The capsule movement
is passively propelled through the intestine by peristalsis
while transmitting color images of the intestine [37]. CE
oﬀers the theoretical advantage of visualizing the whole
small bowel. Nevertheless, the caecum can not be reached in
about 8%–40% of cases [31]. Multiple studies have shown
the impact of CE to diagnose CD-associated changes like
ulcers, erosions, erythema, aphthae, and strictures [38–40].
In the study by Dubcenco et al. CE yielded a sensitivity and
speciﬁcity of 89.6% and 100%, respectively, and a positive
predictive value and negative predictive value of 100% and
76.9%, respectively, for diagnosis of active small-bowel CD
[39]. However, none of these studies used unequivocal gold
standards and the diagnosis of Crohn’s was always supported
by the clinical presentation. Thus, at present diagnosis of
Crohn’s disease cannot be solely based on CE examination.
(i) In case of suspected small bowel, crohn’s disease
without strictures or stenosis capsule endoscopy
should be preferred.
(ii) Balloon-assisted enteroscopy oﬀers the potential to
perform interventions within the small bowel and is
associated with a low complication rate.
2.5. Confocal Laser Endomicroscopy. Confocal laser endomi-
croscopy (CLE) was introduced in 2004 and has rapidly
emerged as a promising approach to obtain real time in
vivo histology during ongoing endoscopy (Figure 5). The
technique is based on tissue illumination with a blue laser
light after topical or systemic application of ﬂuorescence
agents. The most commonly used ﬂuorescence agent is
ﬂuorescein sodium which is administered intravenously
thereby providing systemic tissue staining. Currently, two
FDA-approved and CE-certiﬁed devices are available. One
is integrated into the distal tip of a high-resolution endo-
scope (“integrated”, iCLE; Pentax, Tokyo, Japan) and one
represents a stand-alone confocal probe which is capable
of passing through the working channel of most standard
endoscopes (“probe-based”, pCLE; Cellvizio, Mauna Kea
Technologies, Paris, France) [41].
Kiesslich and coworkers impressively demonstrated that
combination of chromoendoscopy (methylene blue; 0.1%)
and endomicroscopy could detect 4.75-fold more neoplasias
in surveillance colonoscopy of patients with UC compared
to conventional endoscopy. Moreover, 50% less biopsy
specimens were required and CLE could predict neoplastic
changes with a sensitivity, speciﬁcity, and accuracy of about
95%, 98%, and 98%, respectively [42]. Also CLE was feasible
to diﬀerentiate dysplasia-associated lesion or mass (DALM)
and sporadic adenoma (adenoma-like mass; ALM) with a
high accuracy of 97% and an excellent agreement between
CLE and histological diagnosis (κ = 0.91) [43].
One study by Li and coworkers proposed a classiﬁcation
system of inﬂammatory activity in IBD based on a 4-
grade classiﬁcation system of crypt architecture, as well
as by analysis of microvascular alterations and ﬂuores-
cein leakage. Both, assessment of crypt architecture and
ﬂuorescein leakage with CLE showed good correlations
with histological results. Moreover, CLE seemed to be
more accurate than conventional white-light endoscopy
for evaluating macroscopically normal appearing mucosa.
More than half of the patients with normal mucosa seen on6 Gastroenterology Research and Practice
conventional white-light endoscopy showed acute histologic
inﬂammation, whereas no patients with normal mucosa
or with chronic inﬂammation seen on CLE showed acute
inﬂammation on histology [44].
Our group evaluated endomicroscopy for in vivo diag-
nosis of Crohn’s-disease-associated histological changes.
Endomicroscopy was able to diagnose Crohn’s-disease-as-
sociated changes with high accuracy. Furthermore, endo-
microscopy could detect residual macroscopic nonvisible
mucosalinﬂammationaspreciselyashistology(kappavalues
0.8) [45].
(i) CLE can detect more neoplasms in surveillance
colonoscopy of patients with IBD and could predict
neoplastic changes with high accuracy.
(ii) CLE can reliably predict inﬂammatory activity in
IBD during ongoing endoscopy, even in patients with
macroscopically uneventful mucosa.
2.6. Endocytoscopy. Endocytoscopy (EC Figure 6)e n a b l e sin
vivo microscopic imaging at a magniﬁcation up to 1390-
fold magniﬁcation, thereby allowing the analysis of mucosal
structures at the cellular level. EC is based on the principle of
contact light microscopy and therefore only allows visualisa-
tion of the very superﬁcial mucosal layer [46]. The technique
was shown to be reliable for the examination of mucosal
surfaces [47, 48]. In addition, EC could predict neoplasia
in aberrant crypt foci and could distinguish neoplastic from
nonneoplastic colorectal lesions [49, 50]. Our group assessed
thevalueofendocytoscopytodeterminesingleinﬂammatory
cells during ongoing endoscopy in patients with IBD. EC
enabled clear visualization of diﬀerent cellular structures
within the intestinal mucosa, including size, arrangement,
and density of cells. Furthermore, size and shape of nuclei
and the nucleus-to-cytoplasm ratio were visualized. Accord-
ing to these changes, it was possible to distinguish in
real-timeneutrophilicgranulocytes,basophilicgranulocytes,
eosinophilic granulocytes, and lymphocytes by EC [51].
(i) EC harbours the potential to accurately determine
various inﬂammatory mucosal cells during ongoing
endoscopy in IBD and thus the severity of the in-
ﬂammation.
3. Conclusion
Advanced endoscopic imaging in IBD has seen a major
innovation revolution during the last 10 years, including
both vital and virtual chromoendoscopy. By using capsule
endoscopy or balloon-assisted enteroscopy, the endoscopist
is now able to evaluate the entire small bowel and to perform
endoscopic therapies at a place w h e r en oo n eh a sg o n eb e f o r e .
Moreover, recent advances in endoscopic imaging now
enable the endoscopist to obtain real time in vivo histology
during ongoing endoscopy by using endomicroscopy or
endocytoscopy. These emerging imaging modalities enable
the endoscopist to detect and characterize more preneoplas-
tic and neoplastic lesions and to predict mucosal inﬂam-
mation more precisely as compared to conventional white
light endoscopy. Recent eﬀorts have been made to introduce
molecular imaging in IBD by highlighting inﬂammatory
cells and speciﬁc receptors. Results of these trials are highly
anticipated and might open new avenues for diagnostic and
therapeutic strategies in IBD.
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